Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/23/14Vitae Pharmaceuticals Added to Russell 2000(R) and Russell 3000(R) Indexes
FORT WASHINGTON, Pa., Dec. 23, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that it has been added to the Russell 2000® and Russell 3000® indexes, effective as of the close of the market on Friday, December 19, 2014 and as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as bench... 
Download PDFPrinter Friendly Version
12/08/14Vitae Pharmaceuticals Among 2014 Best Places to Work in PA
Marks Fifth Consecutive Year Vitae Has Made the List FORT WASHINGTON, Pa., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced it was named one of the 100 Best Places to Work in PA for the fifth consecutive year. "I'm proud that Vitae has been recognized as a great place to work in Pennsylvania, now for five years in a row," said Jeffrey Hatfield, President and Chief Executive Officer of Vitae. "It's a testament... 
Download PDFPrinter Friendly Version
11/12/14Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results
Conference Call Scheduled for 4:30 p.m. EST Today FORT WASHINGTON, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the third quarter ended September 30, 2014. "The successful completion of our initial public offering in September provides us with additional capital to advance our proprietary pipeline, and, we believe, to achieve a number of key milestones," sai... 
Download PDFPrinter Friendly Version
11/12/14Vitae Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
FORT WASHINGTON, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:45 p.m. EST in New York City. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A r... 
Download PDFPrinter Friendly Version
11/05/14Vitae Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 12, 2014
FORT WASHINGTON, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, November 12, 2014 at 4:30 p.m. EST to discuss third quarter 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 32241... 
Download PDFPrinter Friendly Version
10/27/14Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
FORT WASHINGTON, Pa., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, a... 
Download PDFPrinter Friendly Version
10/23/14Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels BI1181181/VTP-37948 Was Safe and Generally Well-Tolerated With a Profile Supporting Once-Daily Dosing FORT WASHINGTON, Pa., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced positive top-line results from clinical trials in treatment and prevention... 
Download PDFPrinter Friendly Version
09/29/14Vitae Pharmaceuticals Announces Closing of Initial Public Offering
FORT WASHINGTON, Pa., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The aggregate net proceeds to Vitae, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $48.4 million. As previously reported, Vitae Pharmaceuticals ... 
Download PDFPrinter Friendly Version
09/24/14Vitae Pharmaceuticals Announces Pricing of Initial Public Offering
FORT WASHINGTON, Pa., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc., a clinical stage biotechnology company, today announced the pricing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on September 24, 2014 under the ticker symbol "VTAE." In addition, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an... 
Download PDFPrinter Friendly Version
02/20/14Vitae Pharmaceuticals Earns $14 Million Milestone Payment from Boehringer Ingelheim in Alzheimer’s Collaboration.
Milestone achieved for BI’s initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, PA – February 20, 2014 – Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, bestin-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI’s initiation of a Phase 1 clinical trial in the companies’ bet... 
Download PDFPrinter Friendly Version